2021 is expected to become a blockbuster year for global pharma companies producing COVID-19 vaccines with giants Pfizer and Moderna set to gain lion’s share of this year’s vaccine sales.
According to data presented by Finaria.it, BioNTech-Pfizer and Moderna COVID-19 vaccines sales are expected to fetch $14.7 billion in combined revenue to these organizations by 2023
Pharma Intelligence data reveals that there are more than one thousand drugs and vaccines in development targeting the coronavirus disease as of January 11 with more than 60% still in the preclinical phase.
The COVID-19 vaccine developed by the BioNTech-Pfizer duo is set to generate over $3.1 billion in sales during 2021 followed by $1.4 billion in 2022 with a decreased earnings in the next few years.
The major hurdle in the adoption of the BioNTech-Pfizer vaccine is its requirement for ultra-cold storage which is a substantial issue in many countries. The vaccine sold by the duo is expected to generate just $914 million in sales in 2023, almost 3.5 times less than in 2021.
Meanwhile, the Moderna manufactured vaccine is expected to generate over $3.5bn in revenue this year, $400 million more than its rivals BioNTech-Pfizer’s offering. Statistics reveal that the Moderna COVID-19 vaccine’s annual sales revenue is expected to remain around $2.9 billion in the next two years.
Everyone’s vaccine AstraZeneca/Oxford expected to lead in volumes
Data analyzed by Bloomberg show that even though Pfizer and Moderna are set for the lion’s share of 2021 vaccine sales, British-Swedish drug manufacturer AstraZeneca has the highest number of COVID-19 vaccine doses ordered.
With the ability to store at average refrigerator temperatures, AstraZeneca has one of the most significant advantages in the COVID-19 vaccine race and has subsequently secured pre-purchase agreements for almost three billion doses at the beginning of this year.
